In an attempt to bolster its oncology portfolio, Bristol Myers Squibb (BMS) has entered into an agreement to acquire Turning Point Therapeutics for US$76 per share. The deal, which has already been approved by the companies’ boards, values Turning Point at US$4.1 B. The acquisition will provide BMS access to repotrectinib, a mid-stage potential best-in-class ROS1/NTRK inhibitor shown to have a longer duration of response for patients with ROS1-positive first-line non-small cell lung cancer. The drug is expected to launch in 2023 and will be a potential competitor to key players such as Roche’s Rozlytrek® and Pfizer’s Xalkori®.